Grant McFadden

Grant McFadden

Director, Biodesign Center for Immunotherapy, Vaccines and Virotherapy

Bio

Dr. Grant McFadden received a Ph.D. in Biochemistry in 1975, from McGill University in Montreal, Canada.  He has held previous faculty positions at the University of Alberta, the University of Western Ontario, and the University of Florida and was a visiting sabbatical Professor at Harvard Medical School. He was awarded a Canada Research Chair (Tier I) in Molecular Virology in 2001 and in 2005 he was awarded a Howard Hughes Medical Institute International Scholarship. He was inducted as a Fellow of the Royal Society of Canada in 2004, the Canadian Academy of Health Sciences in 2005 and the American Academy of Microbiology in 2007. Dr. McFadden is currently a Professor at Arizona State University and is the Director of the Biodesign Center for Immunotherapy, Vaccines, and Virotherapy (B-CIVV).  He is the co-Editor-in-Chief of the journal PLoS Pathogens, a Senior Editor at Journal of Virology, and was the President of the American Society for Virology 2015-16. Dr. McFadden's lab studies how poxviruses that cause immunosuppression interact with the host immune system. The McFadden lab pioneered the field of viral immune subversion (also called "anti-immunology"), and is credited with the discovery of a wide spectrum of virus-derived inhibitors of the immune system. His lab also investigates host-virus tropism, and the deployment of poxviruses for oncolytic virotherapy for the treatment of cancer, particularly with a rabbit-specific poxvirus called myxoma virus (MYXV). He is also currently developing human clinical trials that exploit virotherapy with MYXV to improve hematopoietic stem cell transplantation therapies for cancer, in collaboration with a biotech company called DNAtrix. To date, McFadden has published over 340 scientific papers and reviews.

Research Interest

  • Discover novel viral proteins that inhibit inflammatory pathways.
  • Analyze the role of intracellular signaling in poxvirus tropism.
  • Develop poxviruses for oncolytic therapeutics to treat cancer.